Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 226

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 226
---
 allocate resources. These financial metrics are used by the CODM to make key
operating decisions, such as the allocation of budget between Research and development and General and Administrative expenses. Segment
assets that are reviewed by the CODM is reported within the Consolidated Balance Sheet as consolidated total assets.

The table
below summarizes the significant expense categories regularly reviewed by the CODM for the period commencing July 24 through December
31, 2024, for the period commencing January 1, 2024 through July 23, 2024 and for the year ended December 31, 2023:

|                             |     | Successor 
 2024      | For the period commencing July 24, 
                            through 
                       December 31, |     | Predecessor 
 2024        | For the period commencing January 1, 
                              through 
                             July 23, |     | 2023 |   Year ended 
 December 31, |
|:----------------------------|:----|:----------|-----------------------------------:|:----|:------------|-------------------------------------:|:----|:-----|-------------:|
| Clinical developments       |     |           |                                171 |     |             |                                  354 |     |      |          490 |
| Payroll expenses            |     |           |                                321 |     |             |                                   98 |     |      |          151 |
| Professional services       |     |           |                                283 |     |             |                                  131 |     |      |          148 |
| Other segments expenses (*) |     |           |                              1,309 |     |             |                                  838 |     |      |          198 |
|                             |     |           |                              2,084 |     |             |                                1,421 |     |      |          987 |

| (*) | Other segments expenses includes share based compensation and other expenses. |

<div align='center'>F-33

REVIUM RX.

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

AS OF JUNE 30, 2025

UNAUDITED

U.S. DOLLARS IN THOUSANDS

INDEX</div>

|                                                         | Page        |
| Condensed Consolidated Balance Sheets                   | F-35        |
| Condensed Consolidated Statements of Comprehensive Loss | F-36        |
| Condensed Consolidated Statements of Changes in Equity  | F-37        |
| Condensed